Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Review of hedge fund launches, closures, trends, regulatory and legal events - week 5

Monday, February 07, 2011

A roundup of the week's hedge fund launches, closures, index performance, trends, regulatory, legal and financial events pertaining to the alternative investments industry.

Last week, we heard of fund launches from Future Capital Partners which brings the Elara Renewable Fund (EIS) and Clean Future (VCT) to market, focusing on high growth potential of the renewable energy investment sector; long/short equity funds were rolled out by Resultant Capital (a former team at Symphony Asset Management) and Courage Capital Management, which also launched a short-biased fund. We learned Nevsky Capital LLPs Martin Taylor will launch an $800m fund, Duma Capital launched a second fund (global macro), Mizuho launched Ovington Capital (multi-strategy), and Fulcrum Asset Management will tap active commodities with a new fund. Former LibertyView partners will launch HudsonView (market neutral), and HedgeForward announced the launch of a CTA focused on OTC foreign exchange markets.

BNY Mellon Asset Management launched a European absolute return fund, Man Group unveiled a hedge fund-linked ETF, Aberdeen brought out onshore versions of their emerging markets and high yield bond funds, and we saw a re-launch from 36 South ('black swan fund').

Absolute Return Partners LLP launched The Global Equity Alpha Fund (UCITS III); and a slew of funds were reported to go live on platforms this quarter with CastleRock ($25m AuM -UCITS) and Sabre ($22AuM - UCITS) funds go ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for